Comparative Pharmacology
Head-to-head clinical analysis: ISOCAINE HYDROCHLORIDE versus LIDOCAINE HYDROCHLORIDE 0 8 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOCAINE HYDROCHLORIDE versus LIDOCAINE HYDROCHLORIDE 0 8 IN DEXTROSE 5 IN PLASTIC CONTAINER.
ISOCAINE HYDROCHLORIDE vs LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isocaine hydrochloride is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials.
Lidocaine is an amide-type local anesthetic that acts by blocking voltage-gated sodium channels in neuronal cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. This stabilizes the neuronal membrane and produces a reversible loss of sensation.
1-2% solution infiltrated subcutaneously or locally, maximum dose 4.5 mg/kg (with epinephrine) or 3.0 mg/kg (without epinephrine), not to exceed 300 mg.
Intravenous administration: 1-1.5 mg/kg bolus, followed by 1-4 mg/min continuous infusion for ventricular arrhythmias. Max dose: 3 mg/kg bolus, 4 mg/min infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged to 6–8 hours; in severe renal impairment, half-life may extend to 4–6 hours.
Terminal elimination half-life is approximately 1.5–2.0 hours after a single IV dose. In patients with heart failure or hepatic impairment, it may be prolonged to >3 hours. After continuous infusion, the half-life may increase due to accumulation.
Renal: Approximately 90% of the dose is excreted as metabolites (primarily conjugated with glucuronic acid) in urine. Fecal: About 10% eliminated unchanged or as metabolites in feces. Biliary excretion is negligible.
Lidocaine is primarily metabolized in the liver by CYP1A2 and CYP3A4 to active metabolites (MEGX, GX). Less than 10% is excreted unchanged in urine. Renal excretion accounts for about 20% of total clearance as metabolites and parent drug; fecal elimination is minimal (<5%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)